Cargando…
Patient selection for cytoreductive surgery and HIPEC for the treatment of peritoneal metastases from colorectal cancer
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a viable option for selected patients with peritoneal metastases (PM) from colorectal origin, resulting in long-term survival and even cure in some cases. However, adequate patient selection for this treatment is cu...
Autores principales: | Simkens, Geert A, Rovers, Koen P, Nienhuijs, Simon W, de Hingh, Ignace H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501638/ https://www.ncbi.nlm.nih.gov/pubmed/28721098 http://dx.doi.org/10.2147/CMAR.S119569 |
Ejemplares similares
-
Effective Strategies to Predict Survival of Colorectal Peritoneal Metastases Patients Eligible for Cytoreductive Surgery and HIPEC
por: Simkens, Geert A, et al.
Publicado: (2021) -
Major influence of postoperative complications on costs of cytoreductive surgery and HIPEC in patients with colorectal peritoneal metastases
por: Simkens, Geert A., et al.
Publicado: (2018) -
Metachronous Peritoneal Metastases After Adjuvant Chemotherapy are Associated with Poor Outcome After Cytoreduction and HIPEC
por: Sluiter, Nina R., et al.
Publicado: (2018) -
Short-term outcome in patients treated with cytoreduction and HIPEC compared to conventional colon cancer surgery
por: Simkens, Geert A., et al.
Publicado: (2016) -
Perioperative Systemic Therapy Versus Cytoreductive Surgery and HIPEC Alone for Resectable Colorectal Peritoneal Metastases: Patient-Reported Outcomes of a Randomized Phase II Trial
por: Bakkers, C., et al.
Publicado: (2023)